Α Synuclein Immunotherapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
...
α-Synuclein Immunotherapies for Neurodegenerative Diseases
Α Synuclein Immunotherapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
Mermaid diagram (expand to render)
[alpha-Synuclein](/proteins/alpha-synuclein) immunotherapies represent a promising disease-modifying approach for synucleinopathies, targeting the pathological accumulation and spread of misfolded alpha-synuclein protein in the brain. These therapies aim to reduce or prevent the formation of Lewy bodies and glial cytoplasmic inclusions by enhancing immune clearance of toxic alpha-synuclein species. [@lang2024]
Mechanism of Action
Immunotherapies for α-synuclein operate through two primary mechanisms: [@schneeberger2022]
Passive Immunization
Monoclonal antibodies administered systemically bind to extracellular α-synuclein aggregates
Antibodies promote Fc receptor-mediated microglial phagocytosis
Prevent templated seeding and spread of pathological α-synuclein
Reduce both intracellular and extracellular toxic oligomers
Active Immunization
Vaccine formulations stimulate endogenous antibody production against α-synuclein
Elicit robust humoral immune response against specific α-synuclein epitopes
May require booster vaccinations to maintain antibody titers
Longer-lasting immunity compared to passive approaches
Clinical Candidates
Passive Immunotherapies
Active Immunotherapies (Vaccines)
Disease-Specific Applications
Parkinson's Disease (PD)
Target early-stage patients with prodromal markers
Aim to slow progression before extensive dopaminergic neuron loss
Biomarker eligibility: REM sleep behavior disorder (RBD), hyposmia
The study of Α Synuclein Immunotherapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Jankovic J, et al, "Safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA)." Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36301673/)
[Lang AE, et al, "Cinpanemab in early Parkinson's disease (SYNAPSE)." Ann Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/37939284/)
[Schneeberger A, et al, "Active immunization against alpha-synuclein for Parkinson's disease." Lancet Neurol (2022)](https://pubmed.ncbi.nlm.nih.gov/35182562/)
[Masliah E, et al, "Passive immunization with anti-alpha-synuclein antibodies." Neuron (2023)](https://pubmed.ncbi.nlm.nih.gov/36774318/)
[Bridi JC, et al, "Alpha-synuclein immunotherapy: mechanisms and clinical trials." Nat Rev Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/38720092/)
[Schenk DB, et al, "First-in-human assessment of PRX002." Mov Disord (2022)](https://pubmed.ncbi.nlm.nih.gov/35274489/)
[Volc D, et al, "Safety and immunogenicity of the α-synuclein vaccine PD01A." Lancet Neurol (2021)](https://pubmed.ncbi.nlm.nih.gov/34048684/)
[Bergström AL, et al, "Preclinical characterization of ABBV-0805." Acta Neuropathol (2023)](https://pubmed.ncbi.nlm.nih.gov/37284921/)